HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An open study of remoxipride, a benzamide derivative, in schizophrenia.

Abstract
Remoxipride is a novel substituted benzamide derivative with specific dopamine-(D2)-receptor blocking properties and selective action on brain mesolimbic functions. Ten inpatients with a DSM-III diagnosis of schizophrenia were treated with the drug in a 6-week open-label study. After 1 week placebo washout, the patients were given stepwise increased doses from 20 to 100 mg t.i.d. Most patients showed a clinically significant improvement; the mean scores in the Brief Psychiatric Rating Scale decreased from 25.8 at baseline to 11.3 at endpoint. Few adverse events were recorded and the rated extrapyramidal symptoms were lower at endpoint than at baseline. No abnormalities in clinical chemistry, haematology, cardiovascular assessments or EEG recordings were seen.
AuthorsL Lindström, G Besev, G Stening, E Widerlöv
JournalPsychopharmacology (Psychopharmacology (Berl)) Vol. 86 Issue 1-2 Pg. 241-3 ( 1985) ISSN: 0033-3158 [Print] Germany
PMID2862658 (Publication Type: Journal Article)
Chemical References
  • Antipsychotic Agents
  • Benzamides
  • Remoxipride
Topics
  • Adult
  • Antipsychotic Agents (adverse effects)
  • Benzamides (adverse effects, therapeutic use)
  • Brief Psychiatric Rating Scale
  • Humans
  • Remoxipride
  • Schizophrenia (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: